FDA Grants Breakthrough Therapy Designation for Avelumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Choueiri TK, Larkin JMG, Oya M, et al First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 4504.
- Escudier B, Tannir NM, McDermott DF, et al. Checkmate 214: Efficacy and safety of nivolumab + ipilimumab vs sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. Paper presented at: ESMO 2017 Congress; September 8–12, 2017; Madrid, Spain. Abstract LBA5.
Disclosure statements are available on the authors' profiles: